Firms Still In Dark Over No-Deal Brexit Supply Routes
Executive Summary
Life science companies need more information on plans for alternative medicine supply routes if the UK leaves the EU without a deal, according to the BioIndustry Association, which says the release of the Operation Yellowhammer document shows the “significant impact” such an outcome would have on the sector.
You may also be interested in...
UK Audit Office Warns On No-Deal Brexit Medicines Supply
A lot of work has gone into planning for the impact of a no-deal Brexit on the UK medicines sector, but with only a month to go much remains to be done to ensure the country has the capacity to handle supply chain disruptions, says the National Audit Office.
Industry Still Awaiting Clarity On Brexit Supply Chain Arrangements
As the Brexit clock continues to tick, industry says it is not impressed by government reassurances that all is well where the continued supply of medicines is concerned.
Will Pharma Firms Bear Cost Of UK Govt’s Latest No-Deal Brexit Supply Plans?
Life science companies are uneasy over the government’s latest proposals for emergency medical supplies to the UK if the country leaves the EU without a deal.